×
About 185,033 results

Lower bevacizumab doses, agents with less systemic exposure may be safer options for ROP
https://www.healio.com/news/ophthalmology/20220203/lower-bevacizumab-doses-agents-with-less-systemic-exposure-may-be-safer-options-for-rop

Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia:...
https://doi.org/10.1080/17512433.2023.2174523
Expert Review of Clinical Pharmacology; Solana-Altabella A, Megías-Vericat JE et. al.

Jan 29th, 2023 - FLT3 inhibitors (FLT3i) are drugs in which there is limited experience and not yet enough information on the mechanisms of absorption, transport, and elimination; but especially on the potential drug-drug interactions (DDIs). There are therefore risks in the management of FLT3i DDIs (i.e., sorafenib, ponatinib, crenolanib, midostaurin, quizartinib, and gilteritinib) and ignoring them can compro...

Baseline characteristics and treatment response predictive of nAMD outcomes with ranibi...
https://doi.org/10.1186/s12886-023-02780-0
BMC Ophthalmology; Tsai CY, Wu CL et. al.

Jan 29th, 2023 - The Ranibizumab AMD Clinical Efficacy Study (RACER) conducted in treatment-naive adult Taiwanese patients with neovascular age-related macular degeneration (nAMD) suggested the importance of early and intensive dosing of ranibizumab for optimal treatment outcomes. This subgroup analysis aims to provide clinical information on treatment response that can potentially guide on maintaining the trea...

Extracellular vesicles: a comprehensive review of their roles as biomarkers and potenti...
https://doi.org/10.1093/ced/llac108
Clinical and Experimental Dermatology; Born LJ, Khachemoune A

Jan 29th, 2023 - Psoriasis is a chronic immune-mediated condition that affects the skin and joints, with current treatments still unable to offer a cure and long-term use of treatments posing health risks. Understanding the pathogenesis of the disease has helped identify new targets that have allowed for the expansion of the therapeutic arsenal. Extracellular vesicles (EVs) have recently emerged as pathophysiol...

A Pediatric Case of Treatment-related Myelodysplastic Syndrome While on Therapy for Pre...
https://doi.org/10.1097/MPH.0000000000002613
Journal of Pediatric Hematology/oncology; McElroy S, Myers GD et. al.

Jan 28th, 2023 - Treatment-related myelodysplastic syndrome (t-MDS) is a rare late effect of cancer therapy. After alkylating agents, this typically occurs years after completion of therapy. Treatment of t-MDS in pediatrics is an allogeneic stem cell transplant, however, the prognosis remains poor. This case demonstrates t-MDS developing in a patient receiving treatment for pre-B acute lymphoblastic leukemia. T...

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognost...
https://doi.org/10.1016/j.eururo.2023.01.001
European Urology; Ernst MS, Navani V et. al.

Jan 28th, 2023 - The combination of immuno-oncology (IO) agents ipilimumab and nivolumab (IPI-NIVO) and vascular endothelial growth factor targeted therapies (VEGF-TT) combined with IO (IO-VEGF) are current standard of care first-line treatments for metastatic renal cell carcinoma (mRCC). To establish real-world clinical benchmarks for IO combination therapies based on the International mRCC Database Consortium...

Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
https://doi.org/10.1371/journal.pone.0278262
PloS One; Longardner K, Wright BA et. al.

Jan 28th, 2023 - Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggesting increased mortality in elderly patients with dementia. However, the reasons for higher mortality are unknown. Expanding on p...

Use of lithium in pediatric bipolar disorders and externalizing childhood- related diso...
https://doi.org/10.2174/1570159X21666230126153105
Current Neuropharmacology; Janiri D, Moccia L et. al.

Jan 28th, 2023 - Lithium is the standard treatment for bipolar disorders (BD) in adults. There is dearth of data on its use in pediatric age. This review aimed to investigate the use of lithium in pediatric bipolar disorder (BD) and other externalizing childhood-related disorders. We applied the Preferred Reporting Items for Systematic Reviews and Meta- analyses criteria (PRISMA) to identify randomized controll...

Exosomes for the diagnosis and treatment of dementia.
https://doi.org/10.1097/YCO.0000000000000842
Current Opinion in Psychiatry; Joo HS, Jeon HY et. al.

Jan 28th, 2023 - Dementia is a syndrome with several possible pathologies. To date, definitive methods for diagnosis and treatment of sub-types of dementia have not been established. Emerging evidence suggests that exosomes can provide important information for the diagnosis and treatment of several subtypes of dementia. This article reviews recent studies on the application of exosomes in dementia. Exosomes ar...

Pathogenesis, immunology, and immune-targeted management of the multisystem inflammator...
https://doi.org/10.1111/pai.13900
Pediatric Allergy and Immunology : Official Publication O... Feleszko W, Okarska-Napierała M et. al.

Jan 28th, 2023 - Multisystem inflammatory syndrome in children (MIS-C) is a rare, but severe complication of coronavirus disease 2019 (COVID-19). It develops approximately 4 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and involves hyperinflammation with multisystem injury, commonly progressing to shock. The exact pathomechanism of MIS-C is not known, but immunological dysr...

Effect of cyclosporine A on focal segmental glomerulosclerosis caused by MYO1E mutation...
https://doi.org/10.1097/MD.0000000000032683
Medicine Li R, Dong W et. al.

Jan 28th, 2023 - Focal segmental glomerulosclerosis (FSGS) describes a renal histologic lesion with diverse causes and pathogenicities. Monogenic abnormalities which are associated with impaired function of podocyte could result in FSGS. Most of genetic FSGS do not respond to immunosuppressive agents and often develop end-stage kidney disease. We reported a case of FSGS caused by myosin1e (MYO1E) mutation, alle...

Factors affecting dialysis duration in children with Shiga toxin-producing Escherichia ...
https://doi.org/10.1007/s00467-022-05839-0
Pediatric Nephrology (Berlin, Germany); Khalid M, Miller C et. al.

Jan 28th, 2023 - Predicting disease severity can be informative for management of HUS. Dialysis requirement, volume depletion, elevated white blood cell counts, very young age, and use of antimotility agents are known factors associated with severe HUS. A retrospective cohort analysis was performed to identify factors associated with dialysis duration using electronic medical record and chart review of 76 child...

UVA1 irradiation attenuates collagen production via Ficz/AhR/MAPK signaling activation ...
https://doi.org/10.1016/j.intimp.2023.109764
International Immunopharmacology; Shi Y, Xiao Y et. al.

Jan 28th, 2023 - Scleroderma is an autoimmune disease mainly characterized by progressive fibrosis of the skin. There are two types of scleroderma, namely localized scleroderma (LS) and systemic sclerosis (SSc); skin lesions in both types of scleroderma are histologically identical. Progressive skin sclerosis induces psychological and ecological burden for scleroderma patients. However, there is no effective tr...

The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib ar...
https://doi.org/10.1016/j.ygyno.2023.01.015
Gynecologic Oncology; Han C, McNamara B et. al.

Jan 28th, 2023 - Ovarian cancer (OC) is associated with the highest gynecologic cancer mortality. The development of novel, effective combinations of targeted therapeutics remains an unmet medical need. We evaluated the preclinical efficacy of the Poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib) and the pan-ErbB inhibitor (neratinib) as single agents and in combination in ovarian cancer cell lines and x...

Practice variability in the perioperative management of pediatric moyamoya disease in N...
https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107029
Journal of Stroke and Cerebrovascular Diseases : the Offi... Sun LR, Hersh DS et. al.

Jan 28th, 2023 - Revascularization surgery decreases the long-term risk of stroke in children with moyamoya but carries an increased risk of perioperative ischemic events. Evidence-based approaches to safe perioperative management of children with moyamoya are limited. We aimed to understand practice variability in perioperative moyamoya care. Neurologists, neurosurgeons, and intensivists practicing in North Am...

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
https://clinicaltrials.gov/ct2/show/NCT03941860

Jan 27th, 2023 - PRIMARY OBJECTIVE: I. To determine whether escalating maintenance therapy with the addition of ixazomib citrate (ixazomib) to lenalidomide improves overall survival among patients who are MRD positive after approximately 1 year of lenalidomide maintenance following an early stem cell transplant (=< 12 months from diagnosis). SECONDARY OBJECTIVES: I. To establish whether progression-free surviva...

Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
https://clinicaltrials.gov/ct2/show/NCT03042988

Jan 27th, 2023 - Primary autonomic failure is a neurodegenerative condition characterized by loss of efferent sympathetic function and severe baroreflex impairment. The clinical hallmark of autonomic failure is disabling orthostatic hypotension, but at least half of patients are also hypertensive while lying down. This supine hypertension can be severe and associated with end-organ damage and worsening of ortho...

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
https://clinicaltrials.gov/ct2/show/NCT04847466

Jan 27th, 2023 - Background: Natural killer (NK) cells are an important component of an anti-tumor immune response. PD-L1 CAR-NK (PD-L1 t-haNKs) is an off the shelf, irradiated human, allogeneic, NK cell line that is frozen, shipped, thawed and then infused. PD-L1 CAR-NK cells have been engineered to have 3 adaptive modifications: Expression of a chimeric antigen receptor (CAR) targeting the tumor-associated an...

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04855136

Jan 27th, 2023 - This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM. The following combinations will be Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone) Arm B will test bb2121 in combination with BMS-986405 (JSMD194) Combinat...

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04675710

Jan 27th, 2023 - PRIMARY OBJECTIVES: I. Demonstrate the efficacy of upfront treatment with neoadjuvant pembrolizumab in combination dabrafenib and trametinib by comparing the complete gross surgical resection rate (R0 or R1 surgical resection) to historical control of 5%. II. Demonstrate the efficacy of pembrolizumab in combination with dabrafenib and trametinib by comparing the overall survival (OS) to histori...